. 2021 Jan 7;16(1):e0245077. doi: 10.1371/journal.pone.0245077

Table 2. Distribution of CD3⁺, CD4⁺ and CD8⁺ T cells, CD19⁺ B cells and CD14⁺ cells among PBMC in the study groups.

	CD3⁺ cells	CD4⁺ cells	CD8⁺ cells	CD19⁺ cells	CD14⁺ cells
SSPE	64.7^*	32.4	26.1	11.6	73.9
SSPE	(15.5–82.7)	(11.4–62.8)	(9.0–45.0)	(1.7–25.7)	(2.4–99.1)
N	50	90	89	27	62
ICON	66.6	34.3	25.2	10.2	76.0
ICON	(0.4–82.5)	(11.8–53.7)	(7.9–47.9)	(2.6–17.5)	(12.1–98.8)
N	44	64	66	22	55
NICON	68.9^*	36.3	27.1	7.0	71.8
NICON	(29.2–80.5)	(12.5–59.2)	(15.7–52.8)	(3.8–16.0)	(5.5–96.0)
N	22	33	36	9	26

Results are presented as median values, and minimum and maximum values are given in parenthesis. SSPE: Subacute sclerosing panencephalitis patients, ICON: Controls with inflammatory diseases, NICON: Controls with non-inflammatory diseases.

*p = 0.02.

Table 2. Distribution of CD3+, CD4+ and CD8+ T cells, CD19+ B cells and CD14+ cells among PBMC in the study groups.

Table 2. Distribution of CD3⁺, CD4⁺ and CD8⁺ T cells, CD19⁺ B cells and CD14⁺ cells among PBMC in the study groups.